This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT06897475 |
|---|---|
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Eli Lilly and Company |
| Enrollment | 200 participants |
| Design | Interventional, Randomized, Parallel, Masking: Double |
| Conditions | Type 2 Diabetes |
| Interventions | LY3457263; Placebo |
| Start | Mar 28, 2025 |
| Primary completion | May 2027 |
| Study completion | Jun 2027 |
| Results posted | Not yet |
| Registry last updated | Sep 14, 2026 |
Compounds on this site that cite this trial
What the registry says the trial is about
The purpose of this study is to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with placebo in participants with type 2 diabetes who are not at HbA1c goal when treated with a stable dose of semaglutide or tirzepatide. Participation in the study will last about 9 months.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Change from Baseline in Hemoglobin A1c (HbA1c) | Baseline, Week 24 |
2 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
